| Structure-based programming of lymph-node targeting in molecular vaccines H Liu, KD Moynihan, Y Zheng, GL Szeto, AV Li, B Huang, DS Van Egeren, ... Nature 507 (7493), 519-522, 2014 | 877 | 2014 |
| Reconstructing the lineage histories and differentiation trajectories of individual cancer cells in myeloproliferative neoplasms D Van Egeren, J Escabi, M Nguyen, S Liu, CR Reilly, S Patel, B Kamaz, ... Cell stem cell 28 (3), 514-523. e9, 2021 | 153 | 2021 |
| Microfluidic squeezing for intracellular antigen loading in polyclonal B-cells as cellular vaccines GL Szeto, D Van Egeren, H Worku, A Sharei, B Alejandro, C Park, K Frew, ... Scientific reports 5 (1), 10276, 2015 | 99 | 2015 |
| Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein D Van Egeren, A Novokhodko, M Stoddard, U Tran, B Zetter, M Rogers, ... PloS one 16 (4), e0250780, 2021 | 68 | 2021 |
| Individually optimal choices can be collectively disastrous in COVID-19 disease control M Stoddard, D Van Egeren, KE Johnson, S Rao, J Furgeson, DE White, ... BMC public health 21, 1-12, 2021 | 29* | 2021 |
| Controlling long-term SARS-CoV-2 infections can slow viral evolution and reduce the risk of treatment failure D Van Egeren, A Novokhodko, M Stoddard, U Tran, B Zetter, MS Rogers, ... Scientific reports 11 (1), 22630, 2021 | 20 | 2021 |
| Transcriptional differences between JAK2-V617F and wild-type bone marrow cells in patients with myeloproliferative neoplasms D Van Egeren, B Kamaz, S Liu, M Nguyen, CR Reilly, M Kalyva, ... Experimental hematology 107, 14-19, 2022 | 14 | 2022 |
| Rapid relaxation of pandemic restrictions after vaccine rollout favors growth of SARS-CoV-2 variants: A model-based analysis D Van Egeren, M Stoddard, A Novokhodko, MS Rogers, ... PloS one 16 (11), e0258997, 2021 | 13* | 2021 |
| Fitness variation in isogenic populations leads to a novel evolutionary mechanism for crossing fitness valleys D Van Egeren, T Madsen, F Michor Communications biology 1 (1), 151, 2018 | 8 | 2018 |
| Vaccines alone cannot slow the evolution of SARS-CoV-2 D Van Egeren, M Stoddard, LF White, NS Hochberg, MS Rogers, B Zetter, ... Vaccines 11 (4), 853, 2023 | 6 | 2023 |
| Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis D Van Egeren, K Kohli, JL Warner, PL Bedard, G Riely, E Lepisto, ... Scientific Reports 12 (1), 19055, 2022 | 4 | 2022 |
| No magic bullet: limiting in-school transmission in the face of variable SARS-CoV-2 viral loads D Van Egeren, M Stoddard, A Malakar, D Ghosh, A Acharya, S Mainuddin, ... Frontiers in Public Health 10, 2022 | 3 | 2022 |
| Endemicity is not a victory: the unmitigated downside risks of widespread SARS-CoV-2 transmission M Stoddard, A Novokhodko, S Sarkar, D Van Egeren, LF White, ... COVID 2 (12), 1689-1709, 2022 | 3 | 2022 |
| The gray swan: model-based assessment of the risk of sudden failure of hybrid immunity to SARS-CoV-2 M Stoddard, L Yuan, S Sarkar, D Van Egeren, LF White, A Chakravarty medRxiv, 2023.02. 26.23286471, 2023 | 2 | 2023 |
| The impact of vaccination frequency on COVID-19 public health outcomes: A model-based analysis M Stoddard, L Yuan, S Sarkar, D van Egeren, S Mangalaganesh, ... medRxiv, 2023.01. 26.23285076, 2023 | 2 | 2023 |
| Shielding under endemic SARS-CoV-2 conditions is easier said than done: a model-based analysis M Stoddard, L Yuan, S Sarkar, M Mazewski, D van Egeren, ... medRxiv, 2023.01. 22.23284884, 2023 | 2 | 2023 |
| Looking under the lamp-post: quantifying the performance of contact tracing in the United States during the SARS-CoV-2 pandemic H Bayly, M Stoddard, D Van Egeren, EJ Murray, J Raifman, A Chakravarty, ... BMC Public Health 24 (1), 595, 2024 | 1 | 2024 |
| Pathways to altered virulence of SARS-CoV-2 LF White, D Van Egeren, M Stoddard, N D'Angelo, H Bayly, M Sagar, ... OSF, 2023 | 1 | 2023 |
| Using game theory to investigate the therapeutic potential of disrupting tumor-microenvironment interactions D Van Egeren, A Chen, M Stoddard, L Yuan, A Chakravarty Cancer Research 84 (6_Supplement), 7378-7378, 2024 | | 2024 |
| Model-derived progression-free survival (mPFS): A better metric for patient-derived xenograft studies A Chen, M Stoddard, L Yuan, D Van Egeren, A Chakravarty, D Bottino Cancer Research 84 (6_Supplement), 6904-6904, 2024 | | 2024 |
